지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2020.1
- 수록면
- 328 - 339 (12page)
이용수
초록· 키워드
오류제보하기
Background/Aims: Several treatment options are currently available for patients with hepatocellular carcinoma (HCC) failing previous sorafenib treatment. We aimed to compare the effectiveness of regorafenib and nivolumab in these patients. Methods: Consecutive HCC patients who received regorafenib or nivolumab after failure of sorafenib treatment were included. Primary endpoint was overall survival (OS) and secondary endpoints were time to progression, tumor response rate, and adverse events. Inverse probability of treatment weighting (IPTW) using the propensity score was conducted to reduce treatment selection bias. Results: Among 150 study patients, 102 patients received regorafenib and 48 patients received nivolumab. Median OS was 6.9 (95% confidence interval [CI], 3.0–10.8) months for regorafenib and 5.9 (95% CI, 3.7–8.1) months for nivolumab (P=0.77 by log-rank test). In multivariable analysis, nivolumab was associated with prolonged OS (vs. regorafenib: adjusted hazard ratio [aHR], 0.54; 95% CI, 0.30–0.96; P=0.04). Time to progression was not significantly different between groups (nivolumab vs. regorafenib: aHR, 0.82; 95% CI, 0.51–1.30; P=0.48). HRs were maintained after IPTW. Objective response rates were 5.9% and 16.7% in patients treated with regorafenib and nivolumab, respectively (P=0.04). Conclusions: After sorafenib failure, the use of nivolumab may be associated with improved OS and better objective response rate as compared to using regorafenib.
목차
등록된 정보가 없습니다.
참고문헌 (35)
참고문헌 신청
Bray F / 2018 / Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries / CA Cancer J Clin 68:394~424
Liu Z / 2019 / The trends in incidence of primary liver cancer caused by specific etiologies : results from the global burden of disease study 2016 and implications for liver cancer prevention / J Hepatol 70:674~683
Villanueva A / 2019 / Hepatocellular carcinoma / N Engl J Med 380:1450~1462
Dika IE / 2017 / Treatment options after sorafenib failure in patients with hepatocellular carcinoma / Clin Mol Hepatol 23:273~279
Bruix J / 2017 / Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment(RESORCE) : a randomised, double-blind, placebo-controlled, phase 3 trial / Lancet 389:56~66
Liu Z / 2019 / The trends in incidence of primary liver cancer caused by specific etiologies : results from the global burden of disease study 2016 and implications for liver cancer prevention / J Hepatol 70:674~683
Villanueva A / 2019 / Hepatocellular carcinoma / N Engl J Med 380:1450~1462
Dika IE / 2017 / Treatment options after sorafenib failure in patients with hepatocellular carcinoma / Clin Mol Hepatol 23:273~279
Bruix J / 2017 / Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment(RESORCE) : a randomised, double-blind, placebo-controlled, phase 3 trial / Lancet 389:56~66
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma
Yonsei Medical Journal
2024 .07
-
Successful Sequential Therapy Involving Regorafenib after Failure of Sorafenib in a Patient with Recurrent Hepatocellular Carcinoma after Liver Transplantation
Journal of Liver Cancer
2020 .01
-
Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program
Cancer Research and Treatment
2017 .01
-
A Case of Achieving Partial Remission with the Combination of Sorafenib and Nivolumab in a Patient with Hepatocellular Carcinoma Showing Disease Progression after Nivolumab Therapy
Journal of Liver Cancer
2019 .01
-
Nivolumab for Advanced Hepatocellular Carcinoma with Multiple Lung Metastases after Sorafenib Failure
Journal of Liver Cancer
2020 .01
-
Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer
Cancer Research and Treatment
2015 .01
-
An Analysis for Survival Predictors for Patients with Hepatocellular Carcinoma Who Failed to Sorafenib Treatment in Pre-regorafenib Era
Journal of Liver Cancer
2019 .01
-
Systemic therapy for advanced hepatocellular carcinoma: consideration for selecting second-line treatment
Journal of Liver Cancer
2021 .09
-
고령 암환자에서의 nivolumab과 pembrolizumab의 유효성과 안전성 평가
한국임상약학회지
2020 .01
-
Nivolumab after sorafenib failure in liver recipients with hepatocellcular carcinoma recurrence
Annals of Hepato-Biliary-Pancreatic Surgery
2021 .12
-
Nivolumab-Induced Alopecia Areata: A Case Report and Literature Review
Annals of Dermatology
2021 .01
-
Real World Experience of Nivolumab in Non-Small Cell Lung Cancer in Korea
Cancer Research and Treatment
2020 .01
-
A Case of Nivolumab-Induced Lichen Planus
Annals of Dermatology
2019 .01
-
Posttransplant sequential adrenal and spine metastasis of hepatocellular carcinoma responsive to combined regorafenib and radiotherapy: a case report
Clinical Transplantation and Research
2023 .03
-
Nivolumab, Pembrolizumab의 임상적 사용 적정성, 유효성 및 안전성 평가
병원약사회지
2020 .01
-
Serum PD-1 Levels Change with Immunotherapy Response but Do Not Predict Prognosis in Patients with Hepatocellular Carcinoma
Journal of Liver Cancer
2019 .01
-
Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy
Clinical and Molecular Hepatology
2015 .01
-
니볼루맙 치료 도중 발생한 폐포자충 폐렴 1예
대한내과학회지
2018 .01
-
Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data
Cancer Research and Treatment
2016 .01
-
Neoadjuvant Nivolumab plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder
Cancer Research and Treatment
2023 .04
이 논문의 저자 정보
최근 본 자료
댓글(0)
0